Our results of visual function protection in ABCA4−/−RDH8−/− mice fed with pellets containing HD-BIO203 for 6 months suggest that this new compound could be well suited for the treatment of the initial stages of the disease and particularly for patients with early and intermediate AMD. Here, ABCA4 is linked to age-related macular degeneration.